Compare Adaptive Biotechnologies Corp (ADPT) vs Remitly Global Inc (RELY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Remitly Global Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Remitly Global Inc trades at $23.13 (market cap $5.08B). The key difference: Remitly Global Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| ADPT | RELY | |
|---|---|---|
Market Cap | $3.33B | $5.08B |
Sector | Health | Technology |
52-Week High | $22.37 | $24.28 |
52-Week Low | $10.24 | $12.20 |
Enterprise Value | $3.19B | $4.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
RELY trades at $24.13, up 1.6% on the day, with strong bullish technical signals from moving averages and a consensus analyst price target of $25.67. The company shows accelerating revenue growth, reaching $1.64 billion in 2025, and has achieved profitability with net income of $67.93 million. Recent news highlights expansion into Canada and new business features driving investor optimism.
Outlook remains positive due to sustained revenue growth and market expansion, though high valuation multiples and overbought RSI levels pose near-term risks. The stock offers growth potential in digital payments but faces execution and competitive pressures in the remittance space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
